Obsidian Therapeutics

CTRL Therapeutics

This company develops cell therapies for solid tumours and microfluidic platforms to identify rare tumour-reactive lymphocytes for cancer patients.

Neogene Therapeutics

This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.

CARGO Therapeutics

This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.

Actym Therapeutics

This biotechnology company develops bacterial immunotherapies to treat solid tumours and fibrotic diseases for patients with advanced cancers.

Swarm Oncology

This biotechnology company develops personalised T cell therapies for patients with advanced solid cancers to achieve long-term remission.

OverT

This biotechnology company develops engineered cell therapies for the treatment of solid tumours in cancer patients.

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

Xilio Therapeutics

This biotechnology company develops tumour-activated immuno-oncology therapies designed to treat patients with solid cancers while reducing systemic side effects.